CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
BCMA 丢失在多发性骨髓瘤新型免疫治疗时代：从生物学到临床实践
英文原题：BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice.
查看英文原题
BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
多发性骨髓瘤（MM）的治疗正在迅速发展。在过去几年中，嵌合抗原受体修饰T细胞和双特异性抗体为复发/难治性MM患者带来了新的治疗选择。目前，B细胞成熟抗原（BCMA）已成为复发/难治性MM中T细胞免疫治疗最常用的靶点。临床数据已证明，CAR-T 细胞和双特异性抗体疗法在经重度治疗的复发/难治性MM中均具有令人鼓舞的疗效和可控的安全性特征。然而，大多数患者在较晚的时间点出现复发，耐药机制在很大程度上仍不清楚。从理论上讲，抗原丢失是肿瘤内在对BCMA靶向免疫治疗产生耐药的潜在机制。因此，需要克服此类耐药的策略。在这篇综述中，我们讨论MM免疫治疗新时代中BCMA丢失的问题。
展开英文摘要原文
The treatment of multiple myeloma (MM) is evolving rapidly. In the past few years, chimeric antigen receptor modified T cells and bispecific antibodies are bringing new treatment options to patients with relapsed/refractory MM.
Currently, B-cell maturation antigen (BCMA) has emerged as the most commonly used target of T-cell-based immunotherapies for relapsed/refractory MM. Clinical data have demonstrated promising efficacy and manageable safety profiles of both chimeric antigen receptor T-cell and bispecific antibody therapies in heavily pretreated relapsed/refractory MM.
However, most patients suffer from relapses at later time points, and the mechanism of resistance remains largely unknown. Theoretically, loss of antigen is a potential tumor-intrinsic resistance mechanism against BCMA-targeted immunotherapies. Strategies to overcome this kind of drug resistance are, therefore, needed. In this review, we discuss the loss of BCMA in the new epoch of immunotherapy for MM.
论文信息
- 作者
- Zhou X、Rasche L、Kortüm KM、Mersi J、Einsele H
- 单位
- Department of Internal Medicine II, University Hospital of Würzburg, Würzburg.Germany
- 文献类型
- 综述
- 期刊
- Haematologica2023 Apr 1
- 原文标识
- PubMed 36263838 · DOI 10.3324/haematol.2020.266841
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →